Houston 503B outsourcing
Houston 503B outsourcing facility insurance — Texas Medical Center anchor cluster.
Houston anchors one of the densest 503B outsourcing facility clusters in the country — Empower Pharmacy is the largest non-PE-backed 503B in the United States; Wells Pharma operates an FDA-registered outsourcing facility focused on hospital pharmacy supply; PCCA (Professional Compounding Centers of America) serves 3,500+ member compounding pharmacies nationally. The Texas Medical Center anchors the surrounding hospital purchase contract network — 60+ institutions including MD Anderson, Texas Children\'s, Memorial Hermann, Houston Methodist, and the broader TMC system.
Cluster characteristics
The Texas Medical Center sets the contractual baseline.
The Texas Medical Center is the largest medical complex in the world by number of institutions and hospital purchase contract volume. Houston 503Bs supplying TMC-affiliated institutions face insurance schedules that have converged on a specific structure: $5M-$10M products liability with the hospital named as additional insured (CG 20 10 + CG 20 37), primary/non-contributory wording (CG 20 01 or equivalent), waiver of subrogation (CG 24 04), 30-day notice of cancellation (manuscript NOC endorsement), and FDA recall extension on the products policy.
The schedule is enforced through automated credentialing platforms — Symplr, Reptrax, Vendormate — which lock the supplier out of the hospital\'s purchasing system if the certificate of insurance does not satisfy the schedule line by line. A 503B with the wrong endorsement set passes evaluation, gets onto the GPO contract, and then watches purchase orders fail to land because the credentialing system flagged the COI.
GLP-1 compounding (semaglutide, tirzepatide) is particularly active in the Houston cluster. Multiple Houston-based 503Bs scaled GLP-1 compounding operations from 2022-2024 under the FDA shortage-list authority; the March 2026 FDA enforcement wave that ended the shortage status has materially changed the underwriting posture for these operators.
Texas regulatory context
Texas State Board of Pharmacy is among the most active.
The Texas State Board of Pharmacy operates an active inspection program for 503A compounding and 503B outsourcing facilities, with documented coordination with FDA inspections post-NECC. Texas Board inspection history materially affects underwriting — operators with recent observations face longer renewal lead times and may need to source from secondary specialty markets at materially higher premium.
USP 797 sterile compounding compliance and USP 800 hazardous drug handling compliance are both actively monitored by the Texas Board. The 2023 USP 797 revision tightened beyond-use dating, environmental monitoring, and competency documentation requirements; Houston 503Bs that updated SOPs to comply have a smoother renewal experience than those that didn\'t.
Premium levels for Houston 503Bs run roughly comparable to or modestly below Atlantic Coast 503B clusters at similar revenue — Texas jurisdictional posture is favorable but the cluster\'s concentration means specialty markets have visibility into individual operator claims experience. Premium spreads of 2-3x between best-in-class and average operators at similar revenue are common, driven primarily by FDA inspection record and claims history.
Free coverage review